Palanisamy, SenthilkumarBalasubramanian, AiyarKanchana, MarimuthuSisubalan, NatarajanSelvakesavan, Rajendran K2025-03-282025-02-2125238027https://dspace.psgrkcw.com/handle/123456789/5414Neurodegenerative diseases, including Alzheimer’s disease (AD)Alzheimer’s disease (AD), Parkinson’s disease (PD)Parkinson’s disease (PD), and amyotrophic lateral sclerosis (ALS), are characterized by progressive neuronal loss and have limited treatment options. CurcuminCurcumin, a bioactive compound derived from turmeric, exhibits multiple neuroprotective properties, making it a potential therapeuticTherapeutics agent for these conditions. However, its clinical use is restricted by poor bioavailability and rapid metabolism. CurcuminCurcumin has shown promise in treating neurodegenerative diseases like AD, PD, and ALS due to its anti-inflammatory, antioxidant, and neuroprotective properties. However, its clinical application is hampered by poor solubility in aqueous solutions, rapid metabolism, and limited bioavailability. These challenges have led researchers to explore innovative strategies to enhance curcuminCurcumin’s therapeutic potential. One promising approach is the use of nanoparticle-based delivery systems, which address these limitations by improving curcuminCurcumin’s stability and permeability across the blood-brain barrier (BBB)Blood-brain barrier (BBB) and providing controlled drug release. NanoparticlesNanoparticles (NPs) offer a viable solution to the challenges associated with curcuminCurcumin delivery. Their unique physicochemical properties, such as enhanced stability and targeted delivery capabilities, help overcome hurdles posed by curcuminCurcumin’s rapid metabolism and poor solubility. For instance, curcumin-loaded nanoparticles (CLNPs) have demonstrated improved drug bioavailability and better brainBrain penetration. Studies have shown that these nanoparticles enhance the therapeutic effects of curcuminCurcumin in neurodegenerative diseases by ensuring sustained release and targeted delivery, thereby addressing key limitations of curcuminCurcumin’s clinical use. Despite their potential benefits, several challenges remain in the application of CLNPs. Achieving consistent and efficient delivery across the BBBBlood-brain barrier (BBB) is a significant obstacle that must be addressed. Additionally, while CLNPs can enhance curcuminCurcumin’s bioavailability, the long-term safetySafety and efficacy of these formulations require further investigation. Potential concerns include immune responses, toxicityToxicity, and the scalability of manufacturing processes. Addressing these challenges through continued research and development will be crucial for the successful clinical translation of CLNPs, ensuring their safetySafety and effectiveness in treating neurodegenerative diseases. This chapter explores the innovative use of nanoparticle-based delivery systems to enhance the therapeutic potential of curcuminCurcumin in treating AD, PD, and ALS.en-USBook chapter